TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02895464

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
Study: NCT02898259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~* Starting lenalidomide Dose (20mg)~* Calculated Creatinine Clearance: \>=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~* Calculated Creatinine Clearance: \>= 30 and \< 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
Study: NCT04160702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivate-The-Bystander (MTB)
Description: MTB is a motivational interviewing intervention designed to increase bystander intervention behaviors. During MTB, participants will discuss their knowledge and experiences with bystander intervention. Participants will then create a plan to increase their bystander intervention behaviors in the future. The interviewer will utilize a variety of motivational interviewing techniques to help guide the conversation towards change (e.g., asking questions in an open-ended manner, reflecting participants' personal values).
Study: NCT02037685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MINT)
Description: MINT has the following basic structure and goals:~* Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.~* Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.~* Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon
Study: NCT04233697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Study: NCT01394627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 100mg x 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05175833

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral probiotics
Description: Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2
Study: NCT02037685

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
Study: NCT03196349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
Study: NCT05175833

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Oral gel containing placebo
Study: NCT00767091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivastigmine
Description: transdermal patch of rivastigmine of 9.5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: transdermal patch of placebo
Study: NCT04317495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Description: After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
Study: NCT02228291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsule containing citrus flavonoid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03223428

Intervention type: DRUG
Intervention: Xermelo
Description: This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
Study: NCT02610595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpixiaozhong particles and Wuse Dietotherapy
Description: Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
Study: NCT03507920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck passive mobilizations
Description: Passive mobilizations performed to the neck of the participant by a Physiotherapist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual contact
Description: Manual contact applied to the neck of the participant by a Physiotherapist
Study: NCT03844165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet change (red rice)
Description: This interventions specifically aims to reduce liver inflammation, by replacing white rice in the diet with equal amounts of red rice and lentils. This will also enable for the research team to tests specific scientific hypotheses regarding the effects of diet on insulin resistance, liver pathology and the gut microbiome in NAFLD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.
Study: NCT04082754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody
Study: NCT03196349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG
Description: Will be randomized to receive open label apixaban of 2.5 mg twice daily
Study: NCT04082754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody
Study: NCT03196349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG
Description: Will be randomized to receive open label rivaroxaban of 10mg daily
Study: NCT04082754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human beta common receptor antagonist monoclonal antibody
Description: Human beta common receptor antagonist monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, same volume and same duration as CSL311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, same volume and same duration as CSL311
Study: NCT03057106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: MEDI4736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: MEDI4736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Tremelimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Tremelimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Drug
Description: Pemetrexed, cisplatin, carboplatin or gemcitibine
Study: NCT02298829

Intervention type: DRUG
Intervention: Subjects Previously Treated with AA4500
Description: no treatment to be administered - observational only
Study: NCT00283075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cancer Macrobead placement in abdominal cavity
Description: 8 macrobeads per kg
Study: NCT03603821

Intervention type: DIAGNOSTIC_TEST
Intervention: CLINICAL ASSESMENT
Description: IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
Study: NCT03617991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
Study: NCT03478111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB008
Description: the study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: basic therapy drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: basic therapy drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: active comparator
Study: NCT02263898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raf kinase inhibitor LGX818
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03778619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG4101(allogeneic Natural Killer cell)
Description: administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 1 x 10\^6 IU/m2, together with MG4101
Study: NCT03516682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
Study: NCT00563186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Admission to a novel hospital ward
Description: Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
Study: NCT01337128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Description: Carotid endarterectomy (CEA) will be performed on the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid stenting (CAS)
Description: Carotid Stenting (CAS) will be performed on these patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurocognitive functions
Description: Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurocognitive functions
Description: Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Levels of biomarkers
Description: Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Levels of biomarkers
Description: Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection of peri-operative embolization
Description: A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detection of peri-operative embolization
Description: A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Validation results
Description: On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Validation results
Description: On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
Study: NCT03424707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW340(pelubiprofen/eperisone)
Description: DW340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelubi(pelubiprofen)
Description: pelubiprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet
Study: NCT02821871

Intervention type: DRUG
Group type: OTHER
Intervention: SP2086

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high fat diet
Study: NCT01530984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
Study: NCT00896207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor SR13668
Description: Given orally as a single dose
Study: NCT03920319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion 150 mg sustained release

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04570319

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bths-08
Description: A capsule containing the probiotic blend (dietary supplement), administered once daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A capsule containing the placebo (dietary supplement), administered one daily for 12 weeks
Study: NCT00896207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor SR13668
Description: Given orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor SR13668
Description: Given orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor SR13668
Description: Given orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor SR13668
Description: Given orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor SR13668
Description: Given orally as a single dose
Study: NCT00882609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Description: Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Description: Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
Study: NCT03512600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 0
Description: Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided.
Study: NCT00879645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide
Description: Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide
Description: Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Sulfide
Description: Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours